COZAAR

LOE Approaching

losartan potassium

NDAORALTABLET
Approved
Apr 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
8

Mechanism of Action

[formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone…

Clinical Trials (5)

NCT00856271Phase 3Completed

Olmesartan Medoxomil Versus Losartan Potassium in Patients With Mild to Moderate Essential Hypertension

Started Aug 2004
287 enrolled
Essential Hypertension
NCT01149473Phase 1Completed

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions

Started Mar 2004
80 enrolled
Healthy
NCT00185094Phase 4Completed

A Comparison of the Effect of Olmesartan Medoxomil, Losartan Potassium, and Atenolol on the Ability of Overweight Patients With High Blood Pressure to Respond to Insulin

Started Feb 2004
60 enrolled
HypertensionInsulin ResistanceMetabolic Syndrome
NCT01149486Phase 1Completed

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Fasting Conditions

Started Jan 2004
20 enrolled
Healthy
NCT00168857Phase 4Completed

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

Started Jul 2003
860 enrolled
HypertensionDiabetic Nephropathies